Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Engene Holdings Inc.
Industry Sector: HealthTechnology
CEO: Ronald H. W. Cooper
Number Of Employees: 57
Enterprise Value: $120,991,762
PE Ratio: -3.51
Exchange/Ticker 1: NASDAQ:ENGN
Exchange/Ticker 2: N/A
Latest Market Cap: $272,730,208
BioCentury | Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Jul 24, 2024
Management Tracks
Trimarchi becomes president, COO of BridgeBio
Plus: New CEO, CFO at Beacon and updates from enGene, Broken String and Nashville
BioCentury | Apr 10, 2024
Management Tracks
PureTech’s Zohar takes CEO role at new portfolio company targeting CNS
Plus: AskBio hires former Prevail CSO, and updates from Illumina, Xencor, Adcentrx, enGene and more
BioCentury | Feb 17, 2024
Finance
Public equity report: Five follow-ons total $875M+, PIPEs keep flowing
Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering
BioCentury | Feb 16, 2024
Management Tracks
CEO Hanson leaving enGene
Plus: Compugen names Mahler CMO and updates from Merck, Navega, RAPT and Ocuphire
BioCentury | Jan 31, 2024
Management Tracks
George Daneker to head clinical oncology at Myriad
Plus: TScan hires Jason Amello as CFO, and updates from CytoDyn, enGene and the Scleroderma Research Foundation
BioCentury | Nov 30, 2023
Management Tracks
Kerr, Zimmermann leaving Generation Bio amid restructuring, headcount cuts
Plus: Sáez becomes Agomab’s chief development officer and updates from Forest Road, PDS, enGene and Pyxis
BioCentury | Nov 1, 2023
Deals
Nov. 1 Quick Takes: AZ takes stake in Cellectis, eyes 25 targets in deal
Plus: RTW acquiring Arix Bioscience, and updates from Aldeyra, AbbVie, Silence, Lilly, Sitryx and more
Items per page:
1 - 8 of 8